Skip to main content
  • Saved

made a Post

Guidance on brolucizumab management recommendations

Guidance on brolucizumab management recommendations

Source :

https://www.sciencedirect.com/science/article/abs/pii/S2173579422000846?via=ihub

Available online 23 July 2022 Brolucizumab, a new generation anti-VEGF, has demonstrated efficacy and safety in AMD in the pivotal HAWK and HARRIER trials. Post-marketing, previously undetected adverse events related to intraocular inflammation have been reported. An independent post hoc review of the pivotal trials puts the rate of IOI at 4.6%.


Conclusion: The adverse events reported are rare, but may be associated with severe and irreversible loss of visual acuity. The recommendations made are intended to facilitate the management of brolucizumab in the routine practice of retinologists, to ensure patient safety and, should any adverse events occur, to minimise their impact on vision.